Human
Toll-like receptor 8 (hTLR8) is expressed in myeloid dendritic cells,
monocytes, and monocyte-derived dendritic cells. Engagement by TLR8
agonists evokes a distinct cytokine profile which favors the development
of type 1 helper T cells. Crystal structures of the ectodomain of
hTLR8 cocrystallized with two regioisomers of a dual TLR7/8-agonistic
N1-substituted imidazoquinolines showed subtle differences in their
interactions in the binding site of hTLR8. We hypothesized that the
potency of a previously reported best-in-class pure TLR8 agonist,
3-pentylquinoline-2-amine, could be further enhanced by “designing
in” functional groups that would mimic key intermolecular interactions
that we had observed in the crystal structures. We performed a focused
exploration of decorating the quinoline core with alkylamino groups
at all possible positions. These studies have led to the identification
of a novel TLR8 agonist that was ∼20-fold more potent than
the parent compound and displays prominent adjuvantic activity in
a rabbit model of immunization.
Toll-like
receptor (TLR)-8 agonists strongly induce the production
of T helper 1-polarizing cytokines and may therefore serve as promising
candidate vaccine adjuvants, especially for the very young and the
elderly. Earlier structure-based ligand design led to the identification
of 3-pentyl-quinoline-2-amine as a novel, human TLR8-specific agonist.
Comprehensive structure–activity relationships in ring-contracted
1-alkyl-1H-benzimidazol-2-amines were undertaken,
and the best-in-class compound, 4-methyl-1-pentyl-1H-benzo[d]imidazol-2-amine, was found to be a pure
TLR8 agonist, evoking strong proinflammatory cytokine and Type II
interferon responses in human PBMCs, with no attendant CD69 upregulation
in natural lymphocytic subsets. The 1-alkyl-1H-benzimidazol-2-amines
represent a novel, alternate chemotype with pure TLR8-agonistic activities
and will likely prove useful not only in understanding TLR8 signaling
but also perhaps as a candidate vaccine adjuvant.
Activation of human toll-like receptor-8 (TLR8), expressed in myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells, evokes a distinct cytokine profile which favors the development of Type 1 helper T cells. Part-structures of the 2-aminobenzimidazole scaffold were examined with a view to identifying structural requisites corresponding to the smallest possible fragment of the benzimidazole core that would allow for retention of TLR8-agonistic activity. TLR8-specific agonistic activity was retained in 1-pentyl-4-phenyl-1H-imidazol-2-amine. The crystal structure of this compound bound to the TLR8 ectodomain displayed binding interactions that are common to other TLR8 agonists. This compound showed markedly attenuated proinflammatory properties in ex vivo human blood models. SAR studies revealed that 4-(2-(benzyloxy)phenyl)-1-pentyl-1H-imidazol-2-amine inhibited TLR signaling in a variety of TLR reporter cell lines, as well as in pharmacologically relevant human blood model systems. A kinase screen of this compound showed relative specificity for calmodulin kinases.
The induction of toll-like receptor 7 (TLR7)-dependent type I interferons (IFN-α/β) from plasmacytoid dendritic cells as well as the production of TLR8-dependent type II interferon (IFN-γ), TNF-α, and IL-12 in myeloid dendritic cells are of importance in generating T helper-1 biased adaptive immune responses. In an effort to identify novel dual TLR7/TLR8-active compounds, we undertook structure-activity relationship studies in pyrimidine 2,4-diamines, focusing on substituents at C5. Several analogues substituted with aminopropyl appendages at C5 displayed dominant TLR8-agonistic activity. N-Butyl-6-methyl-5-(3-morpholinopropyl)pyrimidine-2,4-diamine was found to be a very potent dual TLR7/TLR8 agonist. Employing novel cytokine reporter cell assays, we verified that potency at TLR7 correlates with IFN-α/β production in human blood, whereas IFN-γ and TNF-α induction is largely TLR8-dependent. Dual TLR7/TLR8 agonists markedly upregulate CD80 expression in multiple dendritic cell subsets, providing insight into the immunological basis for the superior adjuvantic properties of such innate immune stimuli.
Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the generation of Type 1 helper T cells. A multiplexed high-throughput screen had led to the identification of N(4)-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed structure-activity relationship study of this chemotype was undertaken. A butyl substituent at N(4) was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to losses in potency, as did the introduction of aromatic bulk. Drawing from our previous structure-based design, several 5-alkylamino derivatives were evaluated. Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N(4)-butyl-6-methylpyrimidine-2,4-diamine. This compound potently induced Th1-biasing IFN-γ and IL-12 in human blood, but lower levels of the proinflammatory cytokines IL-1β, IL-6, and IL-8. These results suggest that the inflammatory and reactogenic propensities of this compound could be considerably more favorable than other TLR8 agonists under evaluation.
Using a multiplexed, reporter gene-based, highthroughput screen, we identified 9-fluoro-7-hydroxy-3-methyl-5-oxo-N-(pyridin-3-ylmethyl)-2,3-dihydro-1H,5H-pyrido-[3,2,1-ij]quinoline-6-carboxamide as a TLR2 agonist. Preliminary structure−activity relationship studies on the carboxamide moiety led to the identification of analogues that induce chemokines and cytokines in a TLR2-dependent manner. These results represent new leads for the development of vaccine adjuvants.
Human toll-like receptor (hTLR)-8 is expressed in myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells. Engagement by TLR8 agonists evokes a distinct cytokine profile which favors the development of type 1 helper T cells. Focused exploration of structure-activity relationships in the imidazoquinolines has led to the identification of several novel human TLR8-specific agonists. The synthetic procedures for best-in-class analogues encompassing four chemotypes are described.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.